MariMed Gelecekteki Büyüme

Future kriter kontrolleri 1/6

MariMed is forecast to grow revenue at 10.7% per annum.

Anahtar bilgiler

n/a

Kazanç büyüme oranı

n/a

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi23.7%
Gelir büyüme oranı10.7%
Gelecekteki özkaynak getirisin/a
Analist kapsamı

Low

Son güncelleme09 Aug 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Kazanç ve Gelir Büyüme Tahminleri

OTCPK:MRMD - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
TarihGelirKazançlarSerbest Nakit AkışıFaaliyetlerden NakitAvg. Analist Sayısı
12/31/2025183N/A5101
12/31/2024164N/A-6N/A1
6/30/2024156-17-218N/A
3/31/2024152-17-516N/A
12/31/2023149-16-128N/A
9/30/2023146-1-106N/A
6/30/20231416-112N/A
3/31/20231379-17-6N/A
12/31/202213413-57N/A
9/30/20221292013N/A
6/30/20221292320N/A
3/31/202212871838N/A
12/31/202112171836N/A
9/30/2021111181530N/A
6/30/202191171020N/A
3/31/2021689511N/A
12/31/2020512-13N/A
9/30/202036-80-52N/A
6/30/202033-89-10-2N/A
3/31/202050-84-28-18N/A
12/31/201946-81-34-24N/A
9/30/201944-10-34-26N/A
6/30/201936-7-32-25N/A
3/31/201913-12-17-8N/A
12/31/201812-14-12-3N/A
9/30/201810-7-19-2N/A
6/30/20188-4-212N/A
3/31/20187-3N/A1N/A
12/31/20176-1N/A2N/A
9/30/201760N/A3N/A
6/30/201750N/A0N/A
3/31/201740N/A0N/A
12/31/201640N/A0N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: Insufficient data to determine if MRMD's forecast earnings growth is above the savings rate (2.5%).

Kazançlar ve Piyasa: Insufficient data to determine if MRMD's earnings are forecast to grow faster than the US market

Yüksek Büyüme Kazançları: Insufficient data to determine if MRMD's earnings are expected to grow significantly over the next 3 years.

Gelir ve Pazar: MRMD's revenue (10.7% per year) is forecast to grow faster than the US market (8.9% per year).

Yüksek Büyüme Geliri: MRMD's revenue (10.7% per year) is forecast to grow slower than 20% per year.


Hisse Başına Kazanç Büyüme Tahminleri


Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: Insufficient data to determine if MRMD's Return on Equity is forecast to be high in 3 years time


Büyüyen şirketleri keşfedin